APP and Alzheimer disease: Another potential therapeutic target for AD is miR-650, which has been found to be significantly increased in the human AD cortex and targets the key AD genes APOE, PSEN1, and CDK5. Overexpression of miR-650 in APP/PSEN1 mice results in the decreased levels of CDK5 and the downstream inhibition of Aβ and neuronal loss (Lin et al., 2023).